References
- Nucynta package insert. Ortho-McNeil-Janssen Pharmaceuticals, Inc. Raritan, NJ. http://www.nucynta.com/sites/all/themes/nucynta/pdf/Nucynta-PI.pdf (accessed April 5, 2012).
- HartrickCT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin Pharmacother 2009;10:2687–2696.
- Bee LA, Bannister K, Rahman W, Dickenson AH. Mu-opioid and noradrenergic α(2)-adrenoreceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. Pain 2011;152:131–139.
- Candiotti KA, Gitlin MC. Review of the effects of opoid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin 2010;26:1677–1684.
- Kavanagh S, Kwong WJ, Hammond GC, Nelson W, Upmalis D, Yang M. Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain. Pain Med 2012;13:1110–1120.
- Casey ER, Scott MG, Tang S, Mullins ME. Frequency of false positive amphetamine screens due to bupropion using the Syva Emit II Immunoassay. J Med Toxicol 2010;7:105–108.
- Collins AA, Merritt AP, Bourland JA. Cross-reactivity of tapentadol specimens with DRI methadone enzyme immunoassay. J Anal Toxicol 2012;36:582–587.